Anticoagulation Forum/LinkedIn
Sep 5, 2025, 12:55
RENOVE and API-CAT Trials: Exploring Secondary VTE Prevention
Anticoagulation Forum shared on LinkedIn:
”Missed it live? The recording of our recent webinar ‘Secondary VTE Prevention: To Reduce or Not to Reduce? A Focus on RENOVE and API-CAT‘ is now available!
Watch it now on our Archived Webinars page.
Dive into one of the most debated questions in anticoagulation—when and how to reduce the dose.
Our expert panel breaks down results from the RENOVE and API-CAT trials, with practical insights you can apply in your practice right away.
What you’ll take away:
- DOAC dosing strategies for extended secondary VTE prevention
- Evidence-based guidance for individualized care
- Real-world tips from leading clinicians
Free for AC Forum members — and joining is quick and free.
Don’t miss the chance to catch up on this timely and dynamic discussion!”
Watch the webinar here.
Find the latest webinars and seminars on thrombosis featured in Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?